The Outcomes-Based Reimbursement Experiment
Executive Summary
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
You may also be interested in...
Gene Therapy Reimbursement Remains A Barrier To Commercialization
Multiple gene therapies have been approved in the last couple of years, but market access and reimbursement for gene therapies remain challenging – a key theme of the Cell & Gene Meeting on the Mesa.
Brilinta Value-Based Contract With UPMC Incorporates Two-Sided Risk
AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.